8-K: Sotera Health: 20th Year Growth, Strong 2025 & 2026 Outlook

Sotera Health announced robust financial results for 2025, marking its 20th consecutive year of revenue growth, and provided an optimistic outlook for 2026.

Summary

• Full-year 2025 net revenues increased 5.7% to $1.164 billion, or 5.2% on a constant currency basis, compared to 2024.
• Full-year 2025 net income increased to $78 million, or $0.27 per diluted share, compared to $44 million, or $0.16 per diluted share, in 2024.
• Full-year 2025 Adjusted EBITDA increased 8.2% to $594 million, or 7.8% on a constant currency basis, compared to 2024.
• Full-year 2025 Adjusted EPS was $0.86, an increase of $0.16 per diluted share, compared to 2024.
• Fourth-quarter 2025 net revenues increased 4.6% to $303 million, or 2.5% on a constant currency basis, compared to the fourth-quarter 2024.
• Fourth-quarter 2025 net income was $35 million, or $0.12 per diluted share, compared to $12 million, or $0.04 per diluted share for the fourth-quarter 2024.
• Fourth-quarter 2025 Adjusted EBITDA increased 2.7% to $157 million, or 0.5% on a constant currency basis, compared to the fourth-quarter 2024.
• Sterigenics delivered strong full-year 2025 net revenues up 8.3% to $756 million (7.7% constant currency) and segment income grew 9.2% to $413 million.
• Nordion delivered strong full-year 2025 net revenues up 8.2% to $188 million (9.1% constant currency) and segment income increased 6.3% to $108 million.
• Nelson Labs full-year 2025 net revenues decreased 3.9% to $220 million (5.0% constant currency), but segment income increased 6.0% to $73 million.
• The Net Leverage Ratio improved to 3.2x as of December 31, 2025, from 3.7x as of December 31, 2024.
• The full-year 2026 outlook projects net revenues growth of 5.0% to 6.5% and Adjusted EBITDA growth of 5.5% to 7.0%, both on a constant currency basis.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, highlighted by consistent revenue growth, significant profit increases, and an improved balance sheet, despite minor segment-specific challenges. The positive 2026 outlook further reinforces confidence in the company's trajectory.

Positives

• Achieved 20th consecutive year of revenue growth, demonstrating business model strength and resiliency.
• Net income significantly increased to $78 million in 2025 from $44 million in 2024.
• Adjusted EBITDA grew 8.2% to $594 million in 2025, reflecting strong operating performance.
• Adjusted EPS increased by $0.16 per diluted share to $0.86 in 2025.
• Sterigenics and Nordion segments delivered strong full-year performance with high-single digit revenue growth.
• Nelson Labs achieved meaningful margin improvement through disciplined operational execution, despite a revenue decrease.
• Net Leverage Ratio improved to 3.2x as of December 31, 2025, from 3.7x in 2024, indicating a strengthened balance sheet.
• The company provided a positive full-year 2026 outlook with projected constant currency revenue growth of 5.0% to 6.5% and Adjusted EBITDA growth of 5.5% to 7.0%.

Negatives

• Nordion's fourth-quarter 2025 net revenues decreased 12.3% due to the timing of cobalt-60 harvest schedules.
• Nelson Labs' full-year 2025 net revenues decreased 3.9% (5.0% on a constant currency basis).
• Nelson Labs' fourth-quarter 2025 segment income growth was partially offset by higher costs and a decline in Expert Advisory Services.

Risks

• Disruption in the availability or supply of, or increases in the price of, ethylene oxide (EO), Cobalt-60 (Co-60), or other direct materials, services, and supplies, potentially due to geopolitical instability and/or sanctions.
• Fluctuations in foreign currency exchange rates.
• Evolving changes in environmental, health, and safety regulations or preferences.
• Health and safety risks associated with the use, storage, transportation, and disposal of potentially hazardous materials such as EO and Co-60.
• The impact and outcome of current and future legal proceedings and liability claims, including litigation related to the use, emissions, and releases of EO from sterilization facilities.
• Allegations of failure to properly perform services and potential product liability claims, recalls, penalties, and reputational harm.
• Compliance with extensive regulatory requirements, associated costs, and any failures to receive or maintain, or delays in receiving, required clearances or approvals.
• Adverse changes in industry trends and competition.
• Market conditions and changes, including inflationary trends and the impact of tariffs, that affect long-term supply contracts with variable price clauses and increase the cost of revenues.
• Business continuity hazards, including supply chain disruptions, federal government shutdowns, and other operational risks.
• Risks of doing business internationally, including global and regional economic and political instability and compliance with various applicable and potentially inconsistent laws and regulations in multiple jurisdictions.
• Ability to increase capacity at existing facilities, build new facilities in a timely and cost-effective manner, and renew leases for leased facilities.
• Ability to attract and retain qualified employees.
• Severe health events or environmental events.
• Cybersecurity incidents, unauthorized data disclosures, and dependence on information technology systems.
• Risks associated with the introduction of artificial intelligence technology.
• Inability to pursue strategic transactions, find suitable acquisition targets, or successfully integrate strategic acquisitions into the business.
• Ability to maintain effective internal control over financial reporting.
• Reliance on intellectual property rights to maintain a competitive position and the risk of claims from third parties regarding infringement or misappropriation.
• Ability to comply with rapidly evolving data privacy and security laws and regulations in various jurisdictions and any ineffective compliance efforts.
• Ability to generate profitability in future periods.
• Impairment charges on goodwill and other intangible assets with indefinite lives, as well as other long-lived assets and intangible assets with definite lives.
• The effects of unionization efforts and labor regulations in countries of operation.
• Adverse changes to tax positions in U.S. or non-U.S. jurisdictions or the interpretation and application of U.S. tax legislation or other changes in U.S. or non-U.S. taxation of operations.
• Significant leverage and how this could adversely affect the ability to raise additional capital, limit the ability to react to challenges, limit flexibility in operating the business through debt agreement restrictions, and/or prevent meeting obligations under existing and future indebtedness agreements.

Future Outlook

Sotera Health projects full-year 2026 net revenues to be between $1.233 billion and $1.251 billion, representing constant currency growth of 5.0% to 6.5%. Adjusted EBITDA is expected to grow 5.5% to 7.0% on a constant currency basis, reaching $632 million to $641 million. Adjusted EPS is anticipated to be in the range of $0.93 to $1.01, with capital expenditures projected between $175 million and $225 million. The company expresses confidence in driving long-term growth, strong free cash flow, and shareholder value, remaining on track to meet financial goals presented at its November 2024 investor day.

Management Comments

• "The Company delivered strong results in 2025, driven by solid execution, increased demand for our mission-critical services, and disciplined financial management."
• "Sterigenics and Nordion delivered strong performance, each achieving high-single digit revenue growth for the year."
• "Nelson Labs delivered growth in core lab testing, while disciplined operational execution drove meaningful margin improvement."
• "This marks two decades of year-over-year revenue growth for the Company, which underscores the strength and resiliency of our business model."
• "As we enter 2026, we are encouraged by our momentum and strengthened balance sheet, and we are confident in our ability to drive long-term growth, strong free cash flow, and shareholder value as we remain on track to meet the financial goals presented at our November 2024 investor day."
• "I would like to thank Alex for his leadership and service the past three years. We are grateful that he will continue to support the Company in an advisory role."
• "We are excited to announce Erikas promotion to General Counsel after demonstrating strong leadership, sound judgment and a deep understanding of our business. Erika is well positioned for continued success in her new role."

Industry Context

StockSavvy.ai notes that Sotera Health operates in the critical healthcare sterilization and lab testing sector, which typically exhibits stable demand due to regulatory requirements and the essential nature of its services. The consistent revenue growth, even with some segment-specific fluctuations, suggests resilience in a market driven by medical device and pharmaceutical production. The focus on mission-critical services positions the company well within the broader healthcare infrastructure, indicating a robust market position despite global economic uncertainties.

Management Changes

Legal Proceedings

• The company settled 97 pending and threatened EO claims against Sterigenics in Illinois pursuant to a term sheet entered into on April 3, 2025.
• The company settled an additional 129 pending and threatened EO claims against Sterigenics in Illinois pursuant to a term sheet entered into on July 23, 2025.
• The company faces ongoing risks related to current and future legal proceedings and liability claims, including litigation related to the use, emissions, and releases of EO from its sterilization facilities.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, significant increases in net income and Adjusted EPS, consistent revenue growth, and an improved balance sheet, which could lead to increased shareholder value.
• Employees: The promotion of Erika Ostrowski to General Counsel demonstrates internal career progression opportunities. Alex Dimitrief's transition to an advisory role ensures continuity of expertise in critical areas.
• Customers: Continued strong demand for mission-critical services indicates robust customer relationships and reliance on Sotera Health's essential solutions.
• Creditors: The improved Net Leverage Ratio (3.2x from 3.7x) and strengthened balance sheet enhance the company's creditworthiness and financial stability.

Next Steps

• Sotera Health management will host a conference call and webcast on February 24, 2026, at 9:00 a.m. Eastern Time to discuss operating highlights and financial results.
• The company will attend the Barclays 28th Annual Global Healthcare Conference on March 11, 2026, at 9:30 a.m. Eastern Time.
• The company will attend the KeyBanc Healthcare Forum on March 17, 2026, at 9:45 a.m. Eastern Time.
• Alex Dimitrief will transition to an outside advisor role to the Company, effective April 1, 2026, to assist with ethylene oxide litigation matters.
• Erika Ostrowski will be promoted to Senior Vice President and General Counsel, effective April 1, 2026.

Key Dates

Recommendation

The company delivered its 20th consecutive year of revenue growth, significantly increased net income and Adjusted EBITDA in 2025, and provided a robust 2026 outlook. The improved net leverage ratio and strong performance across key segments (Sterigenics, Nordion) demonstrate operational strength and financial discipline. While Nelson Labs saw a revenue decrease, margin improvement indicates effective management. The overall trajectory and positive guidance suggest strong future performance, making it an attractive investment.

Keywords

Sotera Health, SHC, Sterilization Solutions, Lab Testing, Healthcare Industry, Financial Results, Earnings, Adjusted EBITDA, Adjusted EPS, Revenue Growth, 2026 Outlook, Corporate Governance, Management Transition, Ethylene Oxide, Cobalt-60, Medical Device Sterilization, Pharmaceutical Testing